Who
Christos Richards
Director
Company insider
Files Form 4 as: Director, Codexis; Director, Coherus Oncology.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $412K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 12 Nov 2014
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —40,983 at $0.00 | filing |
| 14 Jan 2025filed 16 Jan 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —44,150 at $0.00 | filing |
| 10 Jan 2020filed 14 Jan 2020 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Jan 2019filed 30 Jan 2019 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 1 Feb 2018filed 5 Feb 2018 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 17 May 2017filed 19 May 2017 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 24 May 2016filed 26 May 2016 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 13 Nov 2015filed 16 Nov 2015 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Sold | $219K7,988 at $27.38 | filing |
| 13 Nov 2015filed 16 Nov 2015 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Sold | $112K4,012 at $27.93 | filing |
| 12 Nov 2015filed 16 Nov 2015 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Sold | $82K3,000 at $27.23 | filing |
| 1 Apr 2015filed 27 May 2015 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 1 Apr 2015filed 3 Apr 2015 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 12 Nov 2014filed 12 Nov 2014 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code X | $44K26,505 at $1.67 | filing |
| 12 Nov 2014filed 12 Nov 2014 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code J | —2,956 | filing |
| 12 Nov 2014filed 12 Nov 2014 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code C | —39,991 | filing |
| 12 Nov 2014filed 12 Nov 2014 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code C | —12,672 | filing |
| 12 Nov 2014filed 12 Nov 2014 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code C | —2,624 | filing |
| 12 Nov 2014filed 12 Nov 2014 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code X | —26,505 at $0.00 | filing |
News
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026CHRS · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Christos Richards; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.